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Background
With an effective vaccine being sought for the prevention
of HIV transmission, current focus is upon a mucosal vac-
cine strategy providing protection at the viral point of
entry. The full potential of these vaccines can only be real-
ised with the development of successful delivery systems
which are also capable of providing an environment con-
ducive to antigen stability. Previously, rheologically struc-
tured vehicles (RSVs) were formulated to include the
recombinant C-clade HIV-1 envelope protein
CN54gp140, and intra-vaginal immunisation in rabbits
induced significant systemic IgG and specific IgG and IgA
in genital tract secretions. However, CN54gp140 stability
within these aqueous formulations remains a concern.
Here we investigate the formulation of CN54gp140
within modified lyophilised RSV matrices as a means of
providing enhanced protein stabilisation.
Methods
RSV formulations were prepared comprising mucoadhe-
sive (polycarbophil, sodium carboxymethylcellulose) and
vaginal fluid absorbing (polyvinylpyrrolidine) compo-
nents. Using rheological analyses in combination with
dispensing studies, formulations having appropriate flow
properties were chosen for lyophilisation. In vitro release
testing of the lyophilised CN54gp140 formulations were
investigated in PBST, and following prolonged storage at
37°C the antigenicity of CN54gp140 from the lyophilised
RSVs were analysed by ELISA. The antigen CN54gp140
stability profiles of these formulations were compared to
the original aqueous RSV.
Results
CN54gp140 was found to be uniformly distributed
within the lyophilised products and exhibited a sustained
release profile over an 8 hour period during which the
lyophilised 'tablet' underwent complete dissolution in the
surrounding media. While recovery of CN54gp140 from
the aqueous RSV diminished over 9 days, lyophilisation
showed no loss in CN54gp140 antigenicity over 67 days
storage.
Conclusion
Formulation of CN54gp140 within a lyophilised gel
matrix is shown to have a stabilising effect on the antigen
while preserving its sustained release capacity. Such a
mucosal vaccine delivery system may offer numerous
advantages including ease of use, long-term stability and
cold chain avoidance.
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